| 贝伐单抗治疗晚期非小细胞肺癌的系统评价 |
| |
| 引用本文： | 王艇,罗黎力. 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中国实用医药, 2008, 3(5): 1-2 |
| |
| 作者姓名： | 王艇 罗黎力 |
| |
| 作者单位： | 1. 四川大学华西医院肿瘤科,成都,610041
2. 四川大学华西妇产儿童医院 |
| |
| 摘 要： | 目的系统评价贝伐单抗在非鳞状非小细胞肺癌治疗中的临床疗效、安全性和地位。方法采用Cochrane系统评价方法进行资料提取、分析、评价。结果共纳入2个研究，929例晚期非鳞状非小细胞肺癌患者。经meta分析表明贝伐单抗／紫杉醇／卡铂方案的疗效优于紫杉醇／卡铂方案，但发生率相对较高。结论贝伐单抗治疗非鳞状非小细胞肺癌有确切临床疗效，与PC方案联合用药比单纯PC方案更适合晚期非鳞状非小细胞肺癌患者。
|
| 关 键 词： | 肺癌 贝伐单抗 化疗 meta分析 |
A systematic review of bevacizumab for non - small cell lung cancer |
| |
| WANG Ting,LUO Li-li. A systematic review of bevacizumab for non - small cell lung cancer[J]. China Practical Medical, 2008, 3(5): 1-2 |
| |
| Authors: | WANG Ting LUO Li-li |
| |
| Affiliation: | WANG Ting , LUO Li - li(Huaxi Hospital of Sichuang University, Chengdu 610043, China) |
| |
| Abstract: | Objective To compare and evaluate the effectiveness and safety of bevacizumab in the treatment of advanced lung cancer.Methods Search strategy,selection,assessment,data collection and analysis,were undertaken by two authors according to the Cochrane handbook for systematic reviews.Results 2 RCTs including 929 non-square NSCLC patients were included.Meta-analysis shows that BPC regimen has a better therapeutic effect comparing with the PC regimen,while the toxicity is higher in BPC regimen.Conclusion Bevacizumab plus paclitaxel and cisplatin is suitable for the first-line treatment of advanced non-square NSCLC. |
| |
| Keywords: | Lung cancer Chemotherapy Bevacizumab Meta analysis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
